<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529867</url>
  </required_header>
  <id_info>
    <org_study_id>SSC protocol No. 1210</org_study_id>
    <nct_id>NCT00529867</nct_id>
  </id_info>
  <brief_title>Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria</brief_title>
  <official_title>A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dafra Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dafra Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy in children aged 6 - 59
      months with uncomplicated malaria, treated with either conventional artemether/lumefantrine
      tablets(Coartem®) or artemether/ lumefantrine suspension (Co-artesiane®) in Western Kenya
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare PCR corrected cure-rates on day 14 and 28</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine and compare Adequate Clinical and Parasitological Response (ACPR) at days 14 and 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine and compare proportion of children with gametocytes on days 0, 7, 14, and 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitor any possible adverse reactions following use of both drugs</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether/lumefantrine tablets</intervention_name>
    <description>Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine
Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets
Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether/Lumefantrine suspension</intervention_name>
    <description>Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension
Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml
Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Co-Artesiane suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged between 6 and 59 months

          -  Minimum body weight of 5kg

          -  Presence of fever (Temp &gt;/= 37.5°C) or a history of fever in the last 24 hours

          -  Presence of asexual P. falciparum monoinfection

          -  Initial parasite density of between 2,000 and 200,000 asexual parasites/µl of blood

          -  Not suffering from severe and complicated forms of malaria

          -  Able to take drugs under study by the oral route

          -  Parent or guardian gives informed written consent to participate in study

        Exclusion Criteria:

          -  Severe and/or complicated malaria (WHO, 2000 classification), including severe anaemia
             (Hb =/&lt;5 g/dl), two or more seizures in last 24 hrs and hyper-parasitaemia (&gt;200,000
             µl)

          -  Patients treated with mefloquine, halofantrine within the 7 days before Day 0 or with
             quinine salts and artemisinin derivatives within 3 days before Day 0, or
             artemether-lumefantrine 30 days before Day 0

          -  Patients who require intensive care for malaria or another severe concomitant illness
             capable of interfering with the clinical evolution of malaria

          -  Patients with vomiting and/or diarrhoea

          -  Signs of severe malnutrition (defined as follows: children with weight/height ratio
             below 3 standard deviations or below 70% of the median of the WHO standardized
             reference values, or still with symmetrical oedema affecting both feet)

          -  Presence of general danger signs in children below 5 years or other signs of serious
             and complex Plasmodium falciparum, as stated in the present WHO definitions

          -  Patients with known history of heart disease or arrhythmia

          -  History of allergy to artemether/lumefantrine or quinine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Juma, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chulaimbo Health Centre</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>January 17, 2008</last_update_submitted>
  <last_update_submitted_qc>January 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2008</last_update_posted>
  <keyword>Artemether/Lumefantrine suspension</keyword>
  <keyword>P. falciparum malaria</keyword>
  <keyword>children</keyword>
  <keyword>uncomplicated Plasmodium falciparum malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

